Hypercoagulability and thrombosis.
This article has summarized known congenital and acquired alterations of hemostasis leading to thrombosis. Decreases in coagulation inhibitors, including antithrombin III, heparin cofactor II, and protein C and protein S, are of major importance in assessing patients with hypercoagulable states or patients with unexplained thrombosis. Newer assays for components of the fibrinolytic system, plasminogen, t-PA and t-PA inhibitor are also now readily available and are important for defining congenital or acquired fibrinolytic defects leading to hypercoagulability and thrombosis. By judicious use of these assays, combined with clinical evaluation, many patients with thrombosis will have an underlying etiologic blood protein defect defined. Delineating reasons for a thrombotic event is of obvious importance for planning long-term prophylactic therapy and for diagnosing and counseling afflicted family members. In this manner, newly found patients can be treated prophylactically before unalterable morbidity or mortality occurs.
Bick
R L
RL
Department of Medicine, University of California, Los Angeles.
Ucar
K
K
D000990:Antithrombin III / Q000502:physiology; D020152:Antithrombin III Deficiency; D001778:Blood Coagulation Disorders / Q000209:etiology*; D001779:Blood Coagulation Factors / Q000037:antagonists & inhibitors; D005342:Fibrinolysis; D015844:Heparin Cofactor II / Q000172:deficiency / Q000502:physiology; D006801:Humans; D011486:Protein C / Q000502:physiology; D020151:Protein C Deficiency; D017293:Protein S / Q000378:metabolism / Q000502:physiology; D018455:Protein S Deficiency; D013927:Thrombosis / Q000209:etiology*
D001779:Blood Coagulation Factors; D011486:Protein C; D017293:Protein S; D015844:Heparin Cofactor II; D000990:Antithrombin III